Canopy Growth (CGC) vs Cumberland Pharmaceuticals (CPIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed Canopy Growth (CGC) over the past year, gaining 90.2% versus a loss of 44.7%. Over five years, CPIX leads with a +154.7% price change compared with -99.4% for CGC. Canopy Growth is the larger company by market cap ($380.5 million vs $104.6 million), about 3.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGC | CPIX |
|---|---|---|
| Share price | $0.8468 | $6.98 |
| Market cap | $380.47M | $104.58M |
| 1-day change | -3.39% | +1.31% |
| YTD return | -25.72% | +75.38% |
| 1-year return | -44.65% | +90.19% |
| 5-year return | -99.37% | +154.74% |
| Forward P/E | — | 49.86 |
| EPS (TTM) | $-0.45 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.38 | $9.28 |
| 52-week low | $0.81 | $1.85 |
| Distance from 52-week high | -64.42% | -24.78% |
| Analyst consensus | none | — |
| Avg. price target upside | +41.71% | — |
| Average volume | 2.77M | 87.71K |
| Shares outstanding | 423.04M | 14.98M |
| Employees | 1,128 | 88 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Canopy Growth is about 3.6 times larger than Cumberland Pharmaceuticals by market value ($380.47M vs $104.58M).
- CPIX has outperformed CGC by 134.8 percentage points over the past year.
About Canopy Growth
CGC stock →Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel.
Healthcare · Drug Manufacturers - Specialty & Generic · 1,128 employees
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Healthcare · Drug Manufacturers - Specialty & Generic · 88 employees
CGC vs CPIX FAQ
Which is bigger, Canopy Growth or Cumberland Pharmaceuticals?
Canopy Growth (CGC) is larger, with a market capitalization of $380.47M compared with $104.58M for Cumberland Pharmaceuticals (CPIX).
Which stock has performed better over the past year, CGC or CPIX?
CPIX returned +90.19% over the past 12 months, compared with -44.65% for CGC (price return, excluding dividends). Past performance does not predict future results.
Are Canopy Growth and Cumberland Pharmaceuticals in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.